Format

Send to

Choose Destination
J Exp Clin Cancer Res. 2019 May 23;38(1):219. doi: 10.1186/s13046-019-1235-7.

The third-generation EGFR inhibitor AZD9291 overcomes primary resistance by continuously blocking ERK signaling in glioblastoma.

Liu X1,2, Chen X1,2, Shi L1,2, Shan Q1, Cao Q1, Yue C3, Li H1, Li S1, Wang J1, Gao S1,2, Niu M4,5, Yu R6,7.

Author information

1
Insititute of Nervous System Diseases, Affiliated Hospital of Xuzhou Medical University, Xuzhou Medical University, Xuzhou, Jiangsu, China.
2
Department of Neurosurgery, Affiliated Hospital of Xuzhou Medical University, Xuzhou, Jiangsu, China.
3
Surgical Department 9, Xuzhou children's hospital, Xuzhou, Jiangsu, China.
4
Insititute of Nervous System Diseases, Affiliated Hospital of Xuzhou Medical University, Xuzhou Medical University, Xuzhou, Jiangsu, China. msniu24@126.com.
5
Blood Diseases Institute, Xuzhou Medical University, Xuzhou, Jiangsu, China. msniu24@126.com.
6
Insititute of Nervous System Diseases, Affiliated Hospital of Xuzhou Medical University, Xuzhou Medical University, Xuzhou, Jiangsu, China. yu.rutong@163.com.
7
Department of Neurosurgery, Affiliated Hospital of Xuzhou Medical University, Xuzhou, Jiangsu, China. yu.rutong@163.com.

Abstract

BACKGROUND:

Glioblastoma (GBM) is a fatal brain tumor, lacking effective treatment. Epidermal growth factor receptor (EGFR) is recognized as an attractive target for GBM treatment. However, GBMs have very poor responses to the first- and second-generation EGFR inhibitors. The third-generation EGFR-targeted drug, AZD9291, is a novel and irreversible inhibitor. It is noteworthy that AZD9291 shows excellent blood-brain barrier penetration and has potential for the treatment of brain tumors.

METHODS:

In this study, we evaluated the anti-tumor activity and effectiveness of AZD9291 in a preclinical GBM model.

RESULTS:

AZD9291 showed dose-responsive growth inhibitory activity against six GBM cell lines. Importantly, AZD9291 inhibited GBM cell proliferation > 10 times more efficiently than the first-generation EGFR inhibitors. AZD9291 induced GBM cell cycle arrest and significantly inhibited colony formation, migration, and invasion of GBM cells. In an orthotopic GBM model, AZD9291 treatment significantly inhibited tumor survival and prolonged animal survival. The underlying anti-GBM mechanism of AZD9291 was shown to be different from that of the first-generation EGFR inhibitors. In contrast to erlotinib, AZD9291 continuously and efficiently inhibited the EGFR/ERK signaling in GBM cells.

CONCLUSION:

AZD9291 demonstrated an efficient preclinical activity in GBM in vitro and in vivo models. AZD9291 has been approved for the treatment of lung cancer with good safety and tolerability. Our results support the possibility of conducting clinical trials of anti-GBM therapy using AZD9291.

KEYWORDS:

AZD9291; Cell proliferation; EGFR/ERK signaling pathway; GBM

PMID:
31122294
PMCID:
PMC6533774
DOI:
10.1186/s13046-019-1235-7
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for BioMed Central Icon for PubMed Central
Loading ...
Support Center